Drugs / PDNO
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04891354 | Feb 2021 → May 2022 | pulmonary hypertension | Attgeno AB | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PDNO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04891354 ↗ |
| Route | Intravenous | “intravenous (i.v.) infusion” NCT04891354 ↗ |